Repligen Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Repligen Corp.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
/ 
Frequently asked questions
To buy Repligen Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Repligen Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Repligen Corp. is RGEN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Repligen Corp. has its primary listing on NASDAQ. You can trade Repligen Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Repligen Corp. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Repligen Corp. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Repligen Corp..